The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst
: Congrats on a great quarter. So for my first question, are you anticipating any kind of competitive launch in derm in the next year, say, 2021? I know
we've heard about potential competitive launches for 5 -- probably 5 years now, but this time, it kind of feels a little bit different.
And then for my second question was on the diagnostic platform. Is there any limitation to the sample type, say, blood, fecal, urine, even maybe
physical tissue, et cetera? And is there a component that might have a reagent to it?
Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst
: Chris, another question. I'm sorry if this came up, I don't think it did. But about insurance, both the company's involvement in and then a broader
industry question. So first question is, what have you learned about pet insurance and what went well and what did not go so well in your launch
in that space? And separate from Zoetis' involvement in that space, longer term, do you see broader-based interest in pet owners buying insurance?
It seems like everyone with pets sort of gripes about. They're out-of-pocket yet utilization of insurance is quite low. Do you think that's an
employer-mediated phenomenon that needs to be jump-started? Or what are your thoughts on increasing penetration of insurance in the pet
space over time?
|
